|
|
|
Event Videos
|
https://pubmed.ncbi.nlm.nih.gov/32572128/ Int J Obes (Lond). 2020 Aug;44(8):1784-1789. Clinical epidemiological analyses of overweight/obesity and abnormal liver function contributing to prolonged hospitalization in patients infected with COVID-19. Xiang Hu 1, Xiaoqiong Pan 2, Wei Zhou 3, Xuejiang Gu 1, Feixia Shen 1, Bo Yang 4, Zhen Hu 5 Abstract Published on:
Aug-2020
|
https://pubmed.ncbi.nlm.nih.gov/32786149/ Liver transplant Hepatology. 2020 Aug 12.doi: 10.1002/hep.31520. Online ahead of print. Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Towards Personalized Management Published on:
Aug-2020
|
|
https://pubmed.ncbi.nlm.nih.gov/32636123/ Nutr Metab Cardiovasc Dis. 2020 Aug 28;30(9):1564-1572. PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome Diletta Valentini 1, Antonella Mosca 2, Chiara Di Camillo 3, Annalisa Crudele 4, Maria Rita Sartorelli 2, Vittorio Scoppola 3, Luigi Tarani 5, Alberto Villani 3, Massimiliano Raponi 6, Antonio Novelli 7, Anna Alisi 8 Abstract Published on:
Aug-2020
|
https://pubmed.ncbi.nlm.nih.gov/32740536/ Cholestasis Cardiovascular Risk Assessment in Children with Chronic Cholestatic Liver Diseases Kamil Janowski 1, Łukasz Obrycki 2, Mieczysław Litwin 2, Piotr Czubkowski 1, Aldona Wierzbicka-Rucińska 3, Dorota Gliwicz-Miedzińska 1, Irena Jankowska 1, Krzysztof Kostewicz 1, Piotr Socha 1 Abstract Published on:
Jul-2020
|
|
https://pubmed.ncbi.nlm.nih.gov/32826803/ J Pediatr Gastroenterol Nutr. 2020 Aug 20. Use of Dietary Supplements in Pediatric Liver Disease and Transplantation Abstract Background: Dietary supplements are frequently used by healthy individuals and those with chronic medical conditions but may cause damage to the liver. The aim of this study was to examine the prevalence and attitudes of dietary supplement use, and the frequency of disclosure to healthcare providers among parents/caregivers for children with chronic liver disease. Published on:
Aug-2020
|
https://pubmed.ncbi.nlm.nih.gov/32620733/ Hydatid cyst Niger J Clin Pract. 2020 Jul;23(7):1008-1012. Laboratory results and clinical findings of children with hydatid cyst disease T Tartar 1, U Bakal 1, M Sarac 1, A Kazez 1 DOI: 10.4103/njcp.njcp_531_19 Abstract Aims: To study the clinical findings and laboratory results of patients with hydatid disease. Published on:
Jul-2020
|
|
https://pubmed.ncbi.nlm.nih.gov/32838748/ Cholestatic liver disease BMC Pediatr. 2020 Aug 24;20(1):395. Xiao Chen 1 2, Jianshe Wang 1, Yi Lu 1, Xinbao Xie 1, Ying Gu 3, Jos M Latour 4, Yuxia Zhang 5 Abstract Background: Children with chronic cholestatic liver diseases have a high risk of malnutrition. However, nutritional management in China has received little attention, and there has been limited evidence regarding improving these practices. This study aimed to evaluate the feeding status of chronic cholestatic children aged 6-24 months and to explore their parents' experiences with feeding practices. Published on:
Aug-2020
|
https://pubmed.ncbi.nlm.nih.gov/31282035/ Cholestasis JPEN J Parenter Enteral Nutr. 2020 Jul;44(5):951-958. Trends of INR and Fecal Excretion of Vitamin K During Cholestasis Reversal: Implications in the Treatment of Neonates With Intestinal Failure-Associated Liver Disease Duy T Dao 1, Lorenzo Anez-Bustillos 1, Adam M Finkelstein 1, Paul D Mitchell 2, Alison A O'Loughlin 1, Gillian L Fell 1, Meredith A Baker 1, Alexis K Potemkin 1, Kathleen M Gura 3, Mark Puder 1 Abstract Published on:
Jul-2020
|
|
https://pubmed.ncbi.nlm.nih.gov/32814993/ NAFLD Curr Gastroenterol Rep. 2020 Aug 19;22(10):52. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease Abstract Purpose of review: Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children. In this article, we review recent developments in the screening, diagnosis, and treatment of pediatric NAFLD. Published on:
Aug-2020
|
https://pubmed.ncbi.nlm.nih.gov/32451952/ Hepatitis C Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a Philip Rosenthal 1, Michael R Narkewicz 2, Betty B Yao 3, Christopher D Jolley 4, Steven J Lobritto 5, Jessica Wen 6, Jean P Molleston 7, Evelyn K Hsu 8, Maureen M Jonas 9, Jiuhong Zha 3, Li Liu 3, Daniel H Leung 10 Abstract Introduction: To assess the safety, efficacy, and pharmacokinetics of mini-tablet formulations of ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) with or without ribavirin for 12 weeks in children infected with chronic hepatitis C virus (HCV) genotype (GT) 1. Published on:
Jul-2020
|
SMS requests to
9224791366
Ask The Expert
Pediatric Liver Specialists in India
Centres offering Genetic Testing for Pediatric Liver Diseases
Financial Aid Offered by Trusts
